"10.1371_journal.pone.0143492","plos one","2015-12-07T00:00:00Z","Juan Mac√≠as; Luis F L√≥pez-Cort√©s; Francisco T√©llez; Eva Recio; Guillermo Ojeda-Burgos; M¬™Jos√© R√≠os; Antonio Rivero-Ju√°rez; Marcial Delgado; Rivas- Jerem√≠as; Juan A Pineda","Unidad Cl√≠nica de Enfermedades Infecciosas y Microbiolog√≠a, Hospital Universitario de Valme, Sevilla, Spain; Unidad Cl√≠nica de Enfermedades Infecciosas, Microbiolog√≠a y Medicina Preventiva, Hospital Universitario Virgen del Roc√≠o, Instituto de Biomedicina de Sevilla (IBiS), Sevilla, Spain; Unidad de Gesti√≥n Cl√≠nica de Enfermedades Infecciosas y Microbiolog√≠a, Hospital de La L√≠nea de la Concepci√≥n, AGS Campo de Gibraltar, C√°diz, Spain; Unidad de Gesti√≥n Cl√≠nica de Enfermedades Infecciosas, Hospital Virgen de la Victoria, Complejo Hospitalario de M√°laga, M√°laga, Spain; Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen Macarena, Sevilla, Spain; Unidad de Enfermedades Infecciosas, Hospital Universitario Reina Sof√≠a, Instituto Maim√≥nides de Investigaci√≥n Biom√©dica de C√≥rdoba (IMIBIC), C√≥rdoba, Spain; Servicio de Enfermedades Infecciosas, Hospital Regional de M√°laga, Malaga, Spain","Conceived and designed the experiments: JM JAP. Analyzed the data: JM JAP. Contributed reagents/materials/analysis tools: JM LFLC FT ER GOB MJR ARJ MD IRJ. Wrote the paper: JM JAP. Review of results and discussion of interpretation: JM LFLC FT ER GOB MJR ARJ MD IRJ JAP.","The authors of this manuscript have read the journals policy and have the following competing interests: JAP reports having received consulting fees from GlaxoSmithKline, Bristol- Myers Squibb, Abbot, Gilead and Boehringer Ingelheim Pharmaceuticals, Janssen, VIIH and Pfizer. He has received research support from GlaxoSmithKline, Roche, Bristol-Myers Squibb, Schering-Plough, Abbot, Boehringer Ingelheim Pharmaceuticals, Janssen and Pfizer, lecture fees from GlaxoSmithKline, Roche, Abbot, Bristol-Myers Squibb, Boehringer Ingelheim, Schering-Plough Pharmaceuticals, Janssen, VIIV and Gilead, and payment for manuscript preparation from Bristol-Myers Squibb, Boehringer Ingelheim and Roche, and for development of educational presentations from Gilead. JM has been an investigator in clinical trials supported by Roche, Bristol-Myers Squibb and Abbott Pharmaceuticals. He has received lectures fees from Roche, Gilead, Boehringer Ingelheim and Bristol-Myers Squibb, and consulting fees from Boehringer Ingelheim, Bristol Myers-Squibb and Merck Sharp & Dome. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2015","12","Juan Mac√≠as","JM√",10,TRUE,2,NA,2,2,TRUE,TRUE,TRUE,1,"9",FALSE
